The 14th World Clinical Biomarkers & CDx Summit returns this September. This years agenda focuses on strengthening early disease biomarker discovery, clinical biomarker strategy, reimbursement clarity, and drug-diagnostics commercialization. Jill Haizlip, Q² Solutions Global Head of Regulatory will discuss “Evaluating IVDR Compliance for EU Therapeutic Trials” on Friday September 6th at 11:00am.   

We would be delighted to connect with you at booth #47 to discuss how we can help provide actionable insights for post-approval assay testing and fulfil the promise of personalized medicine through Companion Diagnostics.